Neuroplasticity
Neuroplasticity & the Opening Mechanism
How psilocybin creates the neurological conditions for change, and why full spectrum extraction alters its pharmacological profile.
How Psilocybin Acts on the Brain
Psilocybin is a prodrug converted in the body to psilocin, the pharmacologically active compound. Psilocin's primary action is as a partial agonist at serotonin 5-HT2A receptors, with secondary activity at 5-HT2C and 5-HT1A subtypes.
5-HT2A receptors are concentrated in cortical layer V pyramidal neurons, the neurons involved in long-range cortical communication and higher-order cognitive processing. Agonism at these sites increases cortical excitability, disrupts habitual firing patterns, and triggers a downstream cascade of neurochemical changes that together constitute a state of enhanced neuroplasticity.
At sub-perceptual microdosing doses, these effects operate below conscious awareness, influencing the underlying architecture of neural communication without producing the perceptual changes associated with full-dose administration.
"Psilocybin doesn't change the brain's content. It changes its capacity. The neuroplasticity window it opens is the mechanism through which new patterns become possible."
Three Mechanisms That Matter
BDNF Upregulation
Psilocybin reliably increases Brain-Derived Neurotrophic Factor, a protein that supports neuronal growth, synaptic strengthening (long-term potentiation), and the formation of new dendritic spines: the physical substrate of new memories and learned behaviours. This upregulation is among the most replicated findings in psilocybin research.
Default Mode Network Suppression
The DMN is active during self-referential thought and habitual cognition. Psilocybin consistently reduces DMN connectivity in neuroimaging studies. At sub-perceptual doses, this suppression underlies reported improvements in cognitive flexibility and reduced ruminative thought, without perceptual disruption.
Cortical Entropy & Pattern Disruption
Carhart-Harris and colleagues propose that psilocybin increases neural entropy, a measure of the brain's informational complexity and flexibility. Under higher entropy, the brain is less locked into habitual processing and more receptive to novel signal configurations. At microdosing doses, this may translate to enhanced problem-solving and creative association without disorientation.
What the Window Makes Possible
Duration
Animal studies show BDNF upregulation and structural synaptic changes measurable within hours of psilocybin administration, persisting for days to weeks following a single dose. The window is a period, not a moment, during which the conditions for new pattern formation are significantly enhanced above baseline.
What forms within it
A plasticity window does not determine which new patterns form. It creates the conditions in which they form more readily. Set, setting, and intentional practice matter even at sub-perceptual doses. The entourage approach adds herbal adjuncts to direct the plasticity toward specific cognitive or emotional targets.
Consolidation: the next compound's role
The plasticity window creates the opportunity. Consolidation, the stabilisation of new synaptic patterns, is a separate biological process. This is the mechanistic rationale for Amanita muscaria in the entourage stack: muscimol's GABA-A modulation supports the consolidation phase. Explored in Cluster 2.
Full Spectrum: Why It Changes the Profile
The psilocybin fruiting body contains not only psilocybin but additional alkaloids, baeocystin, norbaeocystin, aeruginascin, alongside beta-glucans. Isolated psilocybin removes all of these. Full spectrum extraction preserves the complete alkaloid profile alongside the supporting matrix.
Their pharmacological interactions are not yet fully characterised. What is established is that their removal alters the pharmacological fingerprint, analogous to the distinction between isolated THC and whole-plant cannabis, where additional cannabinoids measurably change the effect profile.
We do not claim full spectrum is clinically superior to isolated psilocybin in controlled trials, this comparison has not been directly studied. We claim the pharmacological fingerprint differs, that a mechanistic rationale for preferring full spectrum exists, and that this distinction matters for consistent practice. That is the basis for Evōke's extraction decision.
What the Evidence Shows
Well established
5-HT2A agonism · BDNF upregulation · DMN suppression · Structural synaptic changes in animal models · Neural entropy increase
Emerging clinical evidence
Sub-perceptual dose effects on human cognition and mood · Controlled microdosing vs placebo trials · Duration of neuroplasticity window post-dose
Not yet directly studied
Full spectrum vs isolated psilocybin pharmacological comparison · Honey matrix delivery effects on bioavailability · Alkaloid interaction profiles
References
- Ly C, et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports. 23(11):3170-3182.
- Carhart-Harris R, et al. (2014). The entropic brain. Frontiers in Human Neuroscience. 8:20.
- Carhart-Harris R, Friston KJ. (2019). REBUS and the anarchic brain. Pharmacological Reviews. 71(3):316-344.
- Vollenweider FX, Kometer M. (2010). The neurobiology of psychedelic drugs. Nature Reviews Neuroscience. 11:642-651.
- Buckner RL, et al. (2008). The brain's default network. Annals of the New York Academy of Sciences. 1124:1-38.
- Szigeti B, et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife. 10:e62878.
- Hasler F, et al. (2004). Pharmacokinetics and pharmacodynamics of psilocybin in healthy humans. Pharmacopsychiatry.
Protocol guidance is for members.
The science is open. How it applies to your practice, dosing, timing, formulation access, is a member benefit.
Request Membership